Prot #VX14-809-106: A Phase 3b, Open-Label Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Cystic Fibrosis and Advanced Lung Disease, Homozygous for the F508del-CFTR Mutation

Project: Research project

Project Details

StatusFinished
Effective start/end date3/30/15 → 3/30/18

Funding

  • Quintiles, Inc. (Prot #VX14-809-106 // Prot #VX14-809-106)
  • Vertex Pharmaceuticals Incorporated (Prot #VX14-809-106 // Prot #VX14-809-106)